1145 Development of a surface engineered lentiviral vector for in vivo generation of CD22-directed CAR T cells

体内 计算机科学 载体(分子生物学) 病毒载体 化学 生物 重组DNA 基因 生物化学 生物技术
作者
Jeffrey J Teoh,Christopher J. Nicolai,Nikole Perdue,Seungjin Shin,Jim Qin,Timothy Gervascio,Alyssa Sheih,Byoung Y. Ryu,Laurie Beitz,Ryan P. Larson
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A1267-A1267 被引量:2
标识
DOI:10.1136/jitc-2024-sitc2024.1145
摘要

Background Advances in autologous CD19 CAR T therapies have transformed treatment for B-cell malignancies (BCM). Despite the transformational benefit, many challenges remain for autologous CAR T therapies, including operational, logistical, and cost burdens, plus the need for alternative treatment strategies for patients who are refractory to approved CD19 CAR T therapies. CD22 is a B-cell specific antigen expressed on most BCMs and autoreactive B cells and is a validated target for CD22-directed CAR T products in BCMs.1–3 Umoja is developing UB-VV400, an off-the-shelf, multidomain fusion (MDF) protein surface engineered lentiviral vector designed to generate CD22-directed CAR T cells in vivo without requiring lymphodepleting chemotherapy. In addition to the CD22-CAR, UB-VV400 delivers a rapamycin-activated cytokine receptor (RACR™) as part of the payload, which is designed to enrich and expand CAR T cells in vivo in the presence of rapamycin. Herein, we describe preclinical evaluations of UB-VV400 ± rapamycin. Methods UB-VV400 lots were manufactured internally by a transient transfection of suspension 293T cells. The transgene payload includes the RACR system and the CD22-directed CAR with 4-1BB and CD3ζ intracellular signaling domains. In vitro studies with UB-VV400 utilized healthy donor and patient PBMCs. Functional assays were performed by co-culturing UB-VV400-generated CAR T cells with target cell lines. In vivo studies were performed in PBMC-humanized NSG MHC-I/II DKO mice bearing systemic tumor, and analyses were performed using in vivo imaging and flow cytometry. Results In vitro treatment of PBMCs with UB-VV400 demonstrated MDF surface engineering mediated selective binding and activation of T cells and subsequent transduction of T cells resulting in expression of RACR and anti-CD22 CAR. UB-VV400 generated CAR T cells mediated antigen-specific tumor cell killing and cytokine secretion in response to CD22hi (Raji) and CD22lo (Nalm6) cells, but not CD22-negative cells (K562, Raji-CD22KO). In humanized mouse studies, UB-VV400 generated CAR T cells that mediated anti-tumor activity. Combination treatment with rapamycin further enriched and expanded CAR T cells in vivo and corresponded with complete tumor cell eradication and prolonged animal survival. Conclusions UB-VV400 demonstrated specific and efficient transduction of T cells, which corresponded with generation of CD22-directed CAR T cells capable of killing both CD 22hi and CD22lo tumor cells in vitro and in vivo. Moreover, the RACR system and administration of rapamycin promoted enrichment and expansion of CAR T in vivo resulting in complete tumor clearance. These nonclinical data support planned studies in R/R LBCL post CD19-directed CAR T therapy. References Fry T, Shah N, Orentas R, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–28. Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33:2854–2866. Tan Y, Cai H, Li C, et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021;11:71.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LYZSh完成签到,获得积分10
1秒前
无辜忆丹发布了新的文献求助10
2秒前
锈雀完成签到,获得积分10
4秒前
starleo完成签到,获得积分10
4秒前
甜蜜阑悦完成签到,获得积分20
5秒前
李昱辰完成签到,获得积分10
5秒前
依霏完成签到,获得积分10
6秒前
dan完成签到,获得积分10
7秒前
7秒前
nanfeng完成签到 ,获得积分10
7秒前
Nidhogg完成签到,获得积分10
7秒前
zzzzz完成签到,获得积分10
8秒前
风飒飒完成签到 ,获得积分10
8秒前
双碳小王子完成签到,获得积分10
8秒前
飘逸沛柔完成签到,获得积分20
10秒前
惜梦完成签到 ,获得积分10
11秒前
123完成签到,获得积分0
12秒前
清秀的落雁完成签到,获得积分10
12秒前
追梦的小孩子完成签到,获得积分10
12秒前
Chavin完成签到,获得积分10
14秒前
yy发布了新的文献求助10
15秒前
无辜忆丹完成签到,获得积分10
16秒前
16秒前
Cyueue完成签到,获得积分10
16秒前
研友_nPxRRn完成签到,获得积分10
17秒前
18秒前
AJ完成签到 ,获得积分10
18秒前
高贵觅山完成签到,获得积分10
18秒前
落寞的秋蝶完成签到 ,获得积分10
18秒前
19秒前
一土它小木登子完成签到,获得积分10
20秒前
害羞平凡完成签到,获得积分10
20秒前
wwd完成签到,获得积分10
21秒前
你说得对完成签到,获得积分10
21秒前
22秒前
姜小时完成签到,获得积分10
23秒前
Cyueue发布了新的文献求助10
23秒前
jason完成签到 ,获得积分10
24秒前
橙花完成签到,获得积分10
26秒前
七七完成签到 ,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923